PUBLIC COMPANY
save$TGTXTG THERAPEUTICS, INC.
$TGTX62.76-2.71%New York, NY, USupdated 13h ago
community read0 votes
🐶 often sniffed alongside
top 3pipeline
3
marketed
1
phase 3
0
catalysts ytd
3
approvals ytd
1
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Marketed2Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
- —A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- phase3An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
- —Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
- phase1A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- phase3A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
- phase2A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
- —A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
🐶 Hiring Signal
News
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 7d ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that